Application of Grabody B, an IGF1R-Mediated BBB Shuttle

Time: 12:00 pm
day: Day One


  •  Various therapeutic antibodies fused with Grabody B showed higher CNS nexposure than mAb in both rodents and non-human primates, proving Grabody B’s versatile applicability
  • The relation between the improved CNS exposure and pharmacodynamic effect was well-established in both rodents and nonhuman primates
  • ABL301, a bispecific antibody composed of anti-alpha synuclein (a-syn) IgG and Grabody B showed better efficacy than anti-a-syn Ab in both Parkinson’s Disease and MSA models